[¹⁸F]Fluorodeoxyglucose-positron emission tomography/computed tomography response evaluation can predict histological response at surgery after induction chemotherapy for oligometastatic bladder cancer

References

• Hautmann RE, de Petriconi RC, Pfeiffer C, et al. Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients. Eur Urol. 2012;61:1039–1047.
   PubMed Web of Science ®Google Scholar
• Meijer RP, Mertens LS, van Rhijn BW, et al. Induction chemotherapy followed by surgery in node positive bladder cancer. Urology. 2014;83:134–139.
   PubMed Web of Science ®Google Scholar
• Ghadjar P, Burkhard FC, Gautschi O, et al. Induction chemotherapy for unresectable urothelial carcinoma of the bladder. BJU Int. 2011;107:894–897.
   PubMed Web of Science ®Google Scholar
• Herr HW, Donat SM, Bajorin DF. Post-chemotherapy surgery in patients with unresectable or regionally metastatic bladder cancer. J Urol. 2001;165:811–814.
   PubMed Web of Science ®Google Scholar
• Zargar-Shoshtari K, Zargar H, Lotan Y, et al. A multi-institutional analysis of outcomes of patients with clinically node positive urothelial bladder cancer treated with induction chemotherapy and radical cystectomy. J Urol. 2016;195:53–59.
   PubMed Web of Science ®Google Scholar
• Sternberg C, Yagoda A, Scher HI, et al. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. J Urol. 1988;139:461–469.
   PubMed Web of Science ®Google Scholar
• Jensen JB, Ulhøi BP, Jensen KM. Prognostic value of lymph-node dissection in patients undergoing radical cystectomy following previous oncological treatment for bladder cancer. Scand J Urol Nephrol. 2011;45:436–443.
   PubMed Web of Science ®Google Scholar
• Liedberg F, Gudjonsson S, Kollberg P, et al. A plea for uniform terminology for patients with urothelial carcinoma treated with chemotherapy prior to radical cystectomy: induction versus neoadjuvant chemotherapy. Eur Urol. 2015;68:742–743.
   PubMed Web of Science ®Google Scholar
• Husband JE, Schwartz LH, Spencer J, et al. Evaluation of the response to treatment of solid tumours - a consensus statement of the International Cancer Imaging Society. Br J Cancer. 2004;90:2256–2260.
   PubMed Web of Science ®Google Scholar
• Graafland NM, Valdés Olmos RA, Teertstra HJ, et al. 18F-FDG PET/CT for monitoring induction chemotherapy in patients with primary inoperable penile carcinoma: first clinical results. Eur J Nucl Med Mol Imaging. 2010;37:1474–1480.
   PubMed Web of Science ®Google Scholar
• Koolen BB, Valdés Olmos RA, Wesseling J, et al. Early assessment of axillary response with 18F-FDG PET/CT during neoadjuvant chemotherapy in stage II-III breast cancer: implications for surgical management of the axilla. Ann Surg Oncol. 2013;20:2227–2235.
   PubMed Web of Science ®Google Scholar
• Mertens L, Fioole-Bruining A, van Rhijn BW, et al. FDG-positron emission tomography/computerized tomography for monitoring the response of pelvic lymph node metastasis to neoadjuvant chemotherapy for bladder cancer. J Urol. 2013;189:1687–1691.
   PubMed Web of Science ®Google Scholar
• Kollberg P, Almquist H, Bläckberg M, et al. [(18)F]Fluorodeoxyglu-cose-positron emission tomography/computed tomography improves staging in patients with high-risk muscle-invasive bladder cancer scheduled for radical cystectomy. Scand J Urol. 2015;49:296–301.
   PubMed Web of Science ®Google Scholar
• Soubra A, Hayward D, Dahm P, et al. The diagnostic accuracy of 18F-fluorodeoxyglucose positron emission tomography and computed tomography in staging bladder cancer: a single-institution study and a systematic review with meta-analysis. World J Urol. 2016;34:1229–1237.
   PubMed Web of Science ®Google Scholar
• Sobin LH, Gospodarowicz MK, Wittekind C. UICC. TNM classification of malignant tumours. 7th ed., Hoboken (NJ): Wiley-Blackwell; 2009.
   Google Scholar
• Anjos DA, Etchebehere EC, Ramos CD, et al. 18F-FDG PET/CT delayed images after diuretic for restaging invasive bladder cancer. J Nucl Med. 2007;48:764–770.
   PubMed Web of Science ®Google Scholar
• Jensen JB, Ulhøi BP, Jensen KM. Lymph node mapping in patients with bladder cancer undergoing radical cystectomy and lymph node dissection to the level of the inferior mesenteric artery. BJU Int. 2010;106:199–205.
   PubMed Web of Science ®Google Scholar
• Young H, Baum R, Cremerius U, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer. 1999;35:1773–1782.
   PubMed Web of Science ®Google Scholar
• Wahl RL, Jacene H, Kasamon Y, et al. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(Suppl 1):122S–150S.
   PubMed Web of Science ®Google Scholar
• Barrington SF, Qian W, Somer EJ, et al. Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging. 2010;37:1824–1833.
   PubMed Web of Science ®Google Scholar
• Ho PL, Willis DL, Patil J, et al. Outcome of patients with clinically node-positive bladder cancer undergoing consolidative surgery after preoperative chemotherapy: the M.D. Anderson Cancer Center Experience. Urol Oncol. 2016;34:59.e1–58.
   Web of Science ®Google Scholar
• Rouanne M, Girma A, Neuzillet Y, et al. Potential impact of 18F-FDG PET/CT on patients selection for neoadjuvant chemotherapy before radical cystectomy. Eur J Surg Oncol. 2014;40:1724–1730.
   PubMed Web of Science ®Google Scholar
• Reese AC, Ball MW, Gandhi N, et al. The utility of an extensive postchemotherapy staging evaluation in patients receiving neoadjuvant chemotherapy for bladder cancer. Urology. 2014;84:358–363.
   PubMed Web of Science ®Google Scholar
• Lu YY, Chen JH, Liang JA, et al. Clinical value of FDG PET or PET/CT in urinary bladder cancer: a systemic review and meta-analysis. Eur J Radiol. 2012;81:2411–2416.
   PubMed Web of Science ®Google Scholar
• Muzi M, O´Sullivan F, Mankoff DA, et al. Quantitative assessment of dynamic PET imaging data in cancer imaging. Magn Reson Imaging. 2012;30:1203–1215.
   PubMed Web of Science ®Google Scholar
• Doot RK, Dunnwald LK, Schubert EK, et al. Dynamic and static approaches to quantifying 18F-FDG uptake for measuring cancer response to therapy, including the effect of granulocyte CSF. J Nucl Med. 2007;48:920–925.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhang C, Liu J, et al. Is 18F-FDG PET accurate to predict neoadjuvant therapy response in breast cancer? A meta-analysis. Breast Cancer Res Treat. 2012;131:357–369.
   PubMed Web of Science ®Google Scholar
• Groheux D, Majdoub M, Sanna A, et al. Early metabolic response to neoadjuvant treatment: FDG PET/CT criteria according to breast cancer subtype. Radiology. 2015;277:358–371.
   PubMed Web of Science ®Google Scholar
• Damrauer JS, Hoadley KA, Chism DD, et al. Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc Natl Acad Sci USA. 2014;111:3110–3115.
   PubMed Web of Science ®Google Scholar
• Coudert B, Pierga JY, Mouret-Reynier MA, et al. Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial. Lancet Oncol. 2014;15:1493–1502.
   PubMed Web of Science ®Google Scholar